Urine-based liquid biopsy is showing signs of great promise for profiling urothelial malignancies, which shed DNA directly into urine. Predicine and collaborators recently presented work at ASCO-GU 2021 demonstrating the superior performance of next generation sequencing (NGS)-based urine liquid biopsy for profiling bladder cancer. In this webinar we will illustrate the potential power of our urine-based NGS liquid biopsy approach for addressing unmet needs in bladder cancer management and clinical trials.
Title: Urine-based NGS liquid biopsy applications in bladder cancer
Date: Tuesday, March 23, 2021
Time: 1:00pm Eastern Standard Time
Duration: 40 minutes
Speaker: Bonnie King, PhD, Associate Director of Translational Medicine, Predicine, Inc.
• Urine-based liquid biopsy treatment selection, disease monitoring, and early cancer detection in bladder cancer
February 2021
View Poster